PD1/PDL1 inhibitorbased immunotherapy in locally advanced or metastatic triplenegative breast cancer: A metaanalysis doi:10.3892/ol.2024.14803Triplenegative breast cancer (TNBC) is a subtype of breast cancer that is negative for oestrogen receptor, progesterone receptor and human epidermal growth factor ...
Combination therapy strategies for improving PD-1 blockadeefficacy: a new era in cancer immunotherapy.3. Landscape of combination therapy trials in breast cancer brainMetastasis.4. Combination immunotherapy: a road map.5. Combination of CTLA-4 and PD-1 blockers for treatment of cancer....
参考文献: [1] Jia H, Truica C I, Wang B, et al. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects[J]. Drug Resistance Updates, 2017, 32: 1-15. [2]Qingsong Huet al.Onc...
近日,南京医科大学殷咏梅、朱一超、丁军利等人与国内研究者合作,在Journal for ImmunoTherapy of Cancer期刊发表的研究成果显示,ARB类降压药竟然可能是“披甲冷肿瘤特攻”,即它们能够专门针对免疫浸润极差、且微环境中堆积大量胶原的难治性肿瘤,成功逆转肿瘤微环境的免疫抑制性,为免疫检查点抑制剂(ICB)起效创造有利条件[...
In breast-conserving surgery, the insensitivity discrimination of negative margins correlating with locoregional recurrence and poor patient outcomes. As for immunotherapy, only 20 %-40 % of the patients respond to the atezolizumab treatment due to the change of PDL1 receptor. Meanwhile, TNBC has ...
Timing of immunotherapy in stage IV non-small cell lung cancer. 8544#Background:Excluding oncogene-driven disease, a combination of cytotoxic chemotherapy and immune checkpoint inhibitor (i.e., anti-PD1/PDL1 inhibitors)... T Komiya,J Zhu,S Takamori,... - 《Journal of Clinical Oncology》 被...
The interaction of programmed cell death 1 ligand 1 (PDL1) with its receptor programmed cell death 1 (PD1) inhibits T cell responses, and blockade of this interaction has proven to be an effective immunotherapy for several different cancers. PDL1 can be expressed on the surface of tumour cell...
245Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1Background Immune checkpoint inhibitors (ICI) improve patient survival in some cancer types but yield limited success in breast cancer. Phase-III clinical trials in triple-negative breast cancer...
FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer.2008; 8:57. [20] Soliman H, Khalil F, Antonia S. PD-L1 Expression is increased in a subset of basal type breast cancer cells. ...
PD-1 and PD-L1 antibodies in cancer: current status and future directions[J]. Cancer Immunology, Immunotherapy, 2017, 66(5): 551-564. [2]Salmaninejad A, Khoramshahi V, Azani A, et al. PD-1 and cancer: molecular mechanisms and polymorphisms[J]. Immunogenetics, 2018, 70(2): 73-86....